DRUG logo

Bright Minds Biosciences (DRUG) Company Overview

Profile

Full Name:

Bright Minds Biosciences Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

March 22, 2021

Indexes:

Not included

Website:

http://brightmindsbio.com

Description:

Bright Minds Biosciences focuses on developing innovative treatments for mental health disorders. The company uses advanced science to create new drugs that aim to improve the lives of patients suffering from conditions like depression and anxiety. Their goal is to provide effective and safe therapies for better mental well-being.

Key Details

Price

$34.01

Market Cap

$239.57 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$0.48(+67.44% YoY)

PE Ratio

-

Annual ROE

-50.25%

Annual Debt To Equity

0.02

Beta

-5.37

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Feb 14, 2022

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jul 14, 2023

Analyst ratings

Recent major analysts updates

Feb 19, 25 HC Wainwright & Co.
Buy
Jan 23, 25 Piper Sandler
Overweight
Jan 10, 25 HC Wainwright & Co.
Buy
Jan 10, 25 Cantor Fitzgerald
Overweight
Nov 25, 24 Baird
Outperform

Screeners with DRUG included

Growing Shares Outstanding
US stocks
Healthcare sector
All stocks
NASDAQ Listed Companies
Biotechnology industry
Small cap stocks
Stocks with low beta
Stocks above SMA 200
NASDAQ earnings calendar

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$34.01
DRUG price is $34.01

Price All-time High

$55.00
DRUG price is currently -38.16% below its historical high of $55.00

Price Analysts Target

-
DRUG price consensus analysts' forecast is unknown

Price Most Recent Change

-2.72%
DRUG price was down -2.72% on Mar 8, 2025

Price YTD Change

-2.97%
DRUG price is down -2.97% since January 1st

Price 3-Year Change

+295.47%
DRUG price is up +295.47% over the past 3 years

Market cap

Market Cap

$239.57 M
DRUG market capitalization is $239.57 million

Market Cap 3-Year Change

+1075.68%
DRUG market capitalization is up +1075.68% over the past 3 years

Market Cap All-time High

$383.60 M
DRUG market capitalization is currently -37.55% below its historical high of $383.60 million

Market Cap Sector Rank

58.02%
DRUG market capitalization is higher than 58.02% of companies in Healthcare sector

Technical

Beta

-5.37
DRUG beta is -5.37

200-day SMA

$19.93
DRUG price is currently +70.65% above its 200-day simple moving average

14-day RSI

44.96
DRUG 14-day relative strength index is 44.96

30-day Relative Volume

0.42
DRUG 30-day relative volume is 0.42

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

-
DRUG annual revenue value is unknown

Annual Revenue Analysts Estimate

-
DRUG annual revenue consensus analysts' forecast is unknown

Annual Revenue 1-Year Change

-
DRUG annual revenue 1-year change is unknown

Annual Revenue Sector Rank

-
DRUG annual revenue is unknown

Profit

Annual Gross Profit

-
DRUG annual gross profit value is unknown

Annual Gross Margin

-
DRUG annual gross profit margin value is unknown

Annual Operating Profit

-$2.07 M
DRUG annual operating income is -$2.07 million

Annual Operating Margin

-
DRUG annual operating profit margin value is unknown

Annual Net Income

-$2.06 M
DRUG annual net profit is -$2.06 million

Annual Net Margin

-
DRUG annual net profit margin value is unknown

EPS

Annual EPS

-$0.48
DRUG annual earnings per share is -$0.48

Annual EPS Analysts Estimate

-$2.35
DRUG annual earnings per share is currently -79.67% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

+67.44%
DRUG annual earnings per share is up +67.44% year-on-year

Annual EPS Sector Rank

71.16%
DRUG annual earnings per share is higher than 71.16% of companies in Healthcare sector

ROA & ROE

Annual ROA

-45.57%
DRUG annual return on assets is -45.57%

Annual ROE

-50.25%
DRUG annual return on equity is -50.25%

EBIT & EBITDA

Annual EBIT

-$2.07 M
DRUG annual earnings before interest & taxes is -$2.07 million

Annual EBITDA

-$2.02 M
DRUG annual EBITDA is -$2.02 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
DRUG price to earnings ratio value is unknown

PE Ratio Sector Rank

-
DRUG price to earnings ratio is unknown

PB Ratio

PB Ratio

5.95
DRUG price to book ratio is 5.95

PB Ratio Sector Rank

85.58%
DRUG price to book ratio is higher than 85.58% of companies in Healthcare sector

PS Ratio

PS Ratio

-
DRUG price to sales ratio value is unknown

PS Ratio Sector Rank

-
DRUG price to sales ratio is unknown

Enterprise value

Enterprise Value

$199.35 M
DRUG enterprise value is $199.35 million

Enterprise Value Sector Rank

57.01%
DRUG enterprise value is higher than 57.01% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-103.64
DRUG EV/EBITDA is -103.64

EV/EBITDA Sector Rank

1.05%
DRUG EV/EBITDA is higher than 1.05% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

11.32
DRUG annual current ratio is 11.32

Annual Quick Ratio

-
DRUG annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.02
DRUG annual debt to equity ratio is 0.02

Annual Interest Coverage Ratio

-
DRUG annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
DRUG piotroski f-score value is unknown

Altman Z-Score

-
DRUG altman z-score value is unknown

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$4.52 M
DRUG annual total assets is $4.52 million

Annual Non Current Assets

$87.10 K
DRUG annual long term assets is $87.10 thousand

Annual Current Assets

$4.43 M
DRUG annual total current assets is $4.43 million

Annual Cash & Cash Equivalents

$4.23 M
DRUG annual cash & cash equivalents is $4.23 million

Equity

Annual Book Value

$4.10 M
DRUG annual book value is $4.10 million

Annual Working Capital

$4.04 M
DRUG annual working capital is $4.04 million

Liabilities

Annual Total Liabilities

$420.60 K
DRUG annual total liabilities is $420.60 thousand

Annual Total Long Term Liabilities

$29.30 K
DRUG annual total long term liabilities is $29.30 thousand

Annual Current Liabilities

$391.30 K
DRUG annual total current liabilities is $391.30 thousand

Annual Accounts Payable

$301.60 K
DRUG annual accounts payable is $301.60 thousand

Debt

Annual Total Debt

$88.10 K
DRUG annual total debt is $88.10 thousand

Annual Total Debt 1-Year Change

+62.85%
DRUG annual total debt is up +62.85% year-on-year

Annual Long Term Debt

$29.30 K
DRUG annual long term debt is $29.30 thousand

Annual Short Term Debt

$58.80 K
DRUG annual short term debt is $58.80 thousand

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$2.07 M
DRUG annual total expenses is $2.07 million

Annual Operating Expenses

$2.07 M
DRUG annual total operating expenses is $2.07 million

Annual Cost Of Goods Sold

-
DRUG annual cost of goods sold value is unknown

Annual SGA

$1.06 M
DRUG annual SGA is $1.06 million

Annual D&A

$53.90 K
DRUG annual depreciation & amortization is $53.90 thousand

Annual Interest Expense

-
DRUG annual interest expense value is unknown

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$1.36 M
DRUG annual cash flow from operations is -$1.36 million

Annual CFO 1-Year Change

+73.88%
DRUG annual cash flow from operations is up +73.88% year-on-year

Annual CFI

-
DRUG annual cash flow from investing activities value is unknown

Annual CFI 1-Year Change

-
DRUG annual cash flow from investing activities 1-year change is unknown

Annual CFF

$595.70 K
DRUG annual cash flow from financing activities is $595.70 thousand

Annual CFF 1-Year Change

-63.29%
DRUG annual cash flow from financing activities is down -63.29% year-on-year

Free CashFlow

Annual FCF

-$1.36 M
DRUG annual free cash flow is -$1.36 million

Annual FCF 1-Year Change

+73.88%
DRUG annual free cash flow is up +73.88% year-on-year

CAPEX

Annual CAPEX

-
DRUG annual capital expenditures value is unknown

Annual CAPEX 1-Year Change

-
DRUG annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

Septerna (SEPN)
ACIU logo
AC Immune SA (ACIU)
Neumora Therapeutics (NMRA)
ELDN logo
Eledon Pharmaceuticals (ELDN)
CDXS logo
Codexis (CDXS)
ANIK logo
Anika Therapeutics (ANIK)
NGNE logo
Neurogene (NGNE)
ZYXI logo
Zynex (ZYXI)
YMAB logo
Y-mAbs Therapeutics (YMAB)

FAQ

  • What is the ticker symbol for Bright Minds Biosciences?
  • Does Bright Minds Biosciences pay dividends?
  • What sector is Bright Minds Biosciences in?
  • What industry is Bright Minds Biosciences in?
  • What country is Bright Minds Biosciences based in?
  • When did Bright Minds Biosciences go public?
  • Is Bright Minds Biosciences in the S&P 500?
  • Is Bright Minds Biosciences in the NASDAQ 100?
  • Is Bright Minds Biosciences in the Dow Jones?
  • When was Bright Minds Biosciences's last earnings report?
  • When does Bright Minds Biosciences report earnings?

What is the ticker symbol for Bright Minds Biosciences?

The ticker symbol for Bright Minds Biosciences is NASDAQ:DRUG

Does Bright Minds Biosciences pay dividends?

No, Bright Minds Biosciences does not pay dividends

What sector is Bright Minds Biosciences in?

Bright Minds Biosciences is in the Healthcare sector

What industry is Bright Minds Biosciences in?

Bright Minds Biosciences is in the Biotechnology industry

What country is Bright Minds Biosciences based in?

Bright Minds Biosciences is headquartered in United States

When did Bright Minds Biosciences go public?

Bright Minds Biosciences's initial public offering (IPO) was on March 22, 2021

Is Bright Minds Biosciences in the S&P 500?

No, Bright Minds Biosciences is not included in the S&P 500 index

Is Bright Minds Biosciences in the NASDAQ 100?

No, Bright Minds Biosciences is not included in the NASDAQ 100 index

Is Bright Minds Biosciences in the Dow Jones?

No, Bright Minds Biosciences is not included in the Dow Jones index

When was Bright Minds Biosciences's last earnings report?

Bright Minds Biosciences's most recent earnings report was on Feb 14, 2022

When does Bright Minds Biosciences report earnings?

The date for Bright Minds Biosciences's next earnings report has not been announced yet